UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Healthcare Professionals

Patients

Investors

14 Recognizing UCB’s Rising Stars: Brittany Blair and Lauren Drowley Recognized by the Healthcare Businesswomen’s Association

Read More Share:

Apr

13 UCB’s Commitment to Understanding Sudden Unexpected Death in Epilepsy (SUDEP)

Read More Share:

Mar

17 Exploring the future of dermatology at AAD 2023

Read More Share:

Mar

16 You Speak, We Listen: How Community Voices Drive Our Work in HS

Read More Share:

Mar

15 Building a Community of Trust in Epilepsy & Rare Syndromes

Read More Share:

Feb

17 Patient-First, Patient-Focused: Our Purpose and Promise

Read More Share:

Jan

20 Employee Spotlight: Ian Crassweller – Leading and Evolving Through Change

Read More Share:

Jan

18 Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

Read More Share:

Jan

06 UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

Read More Share:

Dec

23 UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

Read More Share:

Categories

Archives

Apr

14

Recognizing UCB’s Rising Stars: Brittany Blair and Lauren Drowley Recognized by the Healthcare Businesswomen’s Association

Apr

13

UCB’s Commitment to Understanding Sudden Unexpected Death in Epilepsy (SUDEP)

Mar

17

Exploring the future of dermatology at AAD 2023

Mar

16

You Speak, We Listen: How Community Voices Drive Our Work in HS

Mar

15

Building a Community of Trust in Epilepsy & Rare Syndromes

Feb

17

Patient-First, Patient-Focused: Our Purpose and Promise

Jan

20

Employee Spotlight: Ian Crassweller – Leading and Evolving Through Change

Jan

18

Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

Jan

06

UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

Dec

23

UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

Choose Country

UCB in the U.S.

Patients

Innovation

Disease Areas

Sustainability

Newsroom

Contact

Categories

Archives

Apr

14

Recognizing UCB’s Rising Stars: Brittany Blair and Lauren Drowley Recognized by the Healthcare Businesswomen’s Association

Apr

13

UCB’s Commitment to Understanding Sudden Unexpected Death in Epilepsy (SUDEP)

Mar

17

Exploring the future of dermatology at AAD 2023

Mar

16

You Speak, We Listen: How Community Voices Drive Our Work in HS

Mar

15

Building a Community of Trust in Epilepsy & Rare Syndromes

Feb

17

Patient-First, Patient-Focused: Our Purpose and Promise

Jan

20

Employee Spotlight: Ian Crassweller – Leading and Evolving Through Change

Jan

18

Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

Jan

06

UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

Dec

23

UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

Choose Country

UCB in the U.S.

Patients

Innovation

UCB Worldwide

Disease Areas

Sustainability

Newsroom

Contact